Recent studies have shown that KRT17 has a variety of mechanisms of action in malignant tumors and can inhibit tumor cell proliferation, migration, and invasion by regulating the Akt/mTOR pathway, glucose uptake (Khanom et al., 2016), Wnt signaling pathway, epithelial–mesenchymal transition (EMT) (Wang et al., 2019), and mTOR/S6K1 signaling pathway (Li et al., 2020). This evidence concerns the gene RPS6KB1 and neoplasm.